Literature DB >> 25772170

Eph as a target in inflammation.

Katsuaki Ieguchi1.   

Abstract

Evidence to show that the Eph/ephrin system is involved in inflammation induced by infection, injury, inflammatory diseases, and atherosclerosis has been increased. Although the roles of the Eph/ephrin system in both neural and vascular development as well as cell motility are well documented, its involvement in inflammatory processes has not yet been elucidated in detail. Moreover, the soluble form of artificially oligomerized or dimerized Fc-fused ephrin-A1 has been widely used in in vitro and/or in vivo studies to activate the EphA receptors, whereas its physiological functions as a membrane-anchored protein remain largely unknown. Recent studies using clinical samples reported that the overexpression of Ephs and ephrins in some tumors such as hepatocellular carcinoma positively correlated with both malignancy of tumors and the poor prognosis of cancer patients. However, the molecular mechanisms underlying malignancy of tumors are not fully understood. The author herein summarizes the molecular mechanisms of the Eph/ephrin system involved in the immune system and inflammatory processes. Especially, the author focuses on inflammation-induced physiological changes in vascular endothelial cells leading to vascular hyper-permeability and described them in this review. The author also introduces those that contribute to ephrin-A1-mediated lung metastasis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772170     DOI: 10.2174/1871530315666150316121302

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  6 in total

1.  Activation of EphA4 induced by EphrinA1 exacerbates disruption of the blood-brain barrier following cerebral ischemia-reperfusion via the Rho/ROCK signaling pathway.

Authors:  Fangbin Chen; Zhiyang Liu; Wei Peng; Zhiqin Gao; Hui Ouyang; Tongjun Yan; Songbai Ding; Zhankui Cai; Bin Zhao; Longjin Mao; Zhiyong Cao
Journal:  Exp Ther Med       Date:  2018-07-17       Impact factor: 2.447

2.  Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.

Authors:  Katsuaki Ieguchi; Yoshiro Maru
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 3.  EFNA1 in gastrointestinal cancer: Expression, regulation and clinical significance.

Authors:  Ling-Yu Chu; Bin-Liang Huang; Xu-Chun Huang; Yu-Hui Peng; Jian-Jun Xie; Yi-Wei Xu
Journal:  World J Gastrointest Oncol       Date:  2022-05-15

4.  A Novel EphA2 Inhibitor Exerts Beneficial Effects in PI-IBS in Vivo and in Vitro Models via Nrf2 and NF-κB Signaling Pathways.

Authors:  Li Zeng; Kaixue Li; Hong Wei; Jingjing Hu; Lu Jiao; Shaoyong Yu; Ying Xiong
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

Review 5.  Roles of EphA1/A2 and ephrin-A1 in cancer.

Authors:  Katsuaki Ieguchi; Yoshiro Maru
Journal:  Cancer Sci       Date:  2019-02-15       Impact factor: 6.716

6.  Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions.

Authors:  Katsuaki Ieguchi; Takeshi Tomita; Toshifumi Takao; Tsutomu Omori; Taishi Mishima; Isao Shimizu; Massimiliano Tognolini; Alessio Lodola; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada; Yoshiro Maru
Journal:  Int J Mol Sci       Date:  2021-03-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.